PD-L1 IHC 22C3 pharmDx: Analytical validation on cervical cancer specimens

被引：0
|
作者：
Musser, J. [1 ]
Evans, T. [1 ]
Posch, A. [1 ]
Vasquez, J. [1 ]
Tabuena-Frolli, S. [1 ]
Apostolaki, A. [1 ]
Kulangara, K. [1 ]
机构：
[1] Agilent Technol, Santa Clara, CA USA
来源：
VIRCHOWS ARCHIV | 2022年 / 481卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
PS-08-011
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 50 条
  • [1] EXTERNAL REPRODUCIBILITY OF PD-L1 IHC 22C3 PHARMDX FOR CERVICAL CANCER AT CPS ≥ 1 AND CPS ≥ 10
    Cherryholmes, Greg
    Posch, Alexander
    Tabuena-Frolli, Siena
    Vasquez, Jesse
    Evans, Tiffany
    La Placa, Chris
    Kersch, Kristopher
    Apostolaki, Angeliki
    Juco, Jonathan
    Kulangara, Karina
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A44 - A44
  • [2] A Comparative Study of PD-L1 IHC 28-8 pharmDx and PD-L1 IHC 22C3 pharmDx on Malignancies from the Lung
    Skov, Birgit
    Skov, Torsten
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S815 - S816
  • [3] Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx
    Kalpakolf, Megan
    Hung, Stephanie
    Musser, Jeanette
    Roach, Charlotte
    Apostolaki, Angeliki
    Vilardo, Monika
    Peltz, Lindsay
    Watts, Brittany
    LaPlaca, Chris
    Tabuena-Frolli, Siena
    DiMaio, Michael A.
    Welcher, Rosanne
    Kulangara, Karina
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2021, 29 (09) : 667 - 673
  • [4] External Reproducibility of PD-L1 IHC 22C3 pharmDx on Breast Cancer Specimens at CPS ≥ 1 and CPS ≥ 10 Cutoffs
    Steiner, Lori
    Barreto, Joseph
    Olander, Emily
    Kell, Donna
    Tabuena-Frolli, Siena
    Polewski, Monika
    CANCER RESEARCH, 2024, 84 (09)
  • [5] Impact of prolonged ischemia and fixation time on tonsil specimens stained with PD-L1 IHC 22C3 pharmDx
    Roach, C.
    Kersch, K.
    Musser, J.
    Tabuena-Frolli, S.
    Hund, S.
    Kulangara, K.
    VIRCHOWS ARCHIV, 2024, 485 : S347 - S347
  • [6] Consistent and highly reproducible results with PD-L1 22C3 IHC pharmDx in external validation studies on human cancer tissues
    Musser, J.
    Carnahan, J.
    Roach, C.
    Hund, S.
    Guerrero, L.
    Jansson, M.
    Hanks, D.
    Welcher, R.
    Kulangara, K.
    VIRCHOWS ARCHIV, 2018, 473 : S117 - S117
  • [7] Analytical comparison of a PD-L1 22C3 antibody LDT protocol on the BenchMark XT and PD-L1 IHC 22C3 pharmDx: Analysis of pan-tumor and esophageal cancer samples.
    Vainer, Gilad W.
    Zatara, Ghadeer
    Huang, Lingkang
    Emancipator, Kenneth
    Nuti, Shanthy
    CANCER RESEARCH, 2021, 81 (13)
  • [8] The Impact of Tumor Heterogeneity on PD-L1 Status, using PD-L1 IHC 22C3 pharmDx on Multiple Human Cancer Tissues
    Ruvalcaba-Rodarte, Jim
    Hund, Stephanie
    Moquin, Deanna
    Ponce, Francisco
    Adams, Micki
    Morones, Amber
    Borgert, Kiera
    Kersch, Kris
    Kulangara, Karina
    Kalpakoff, Megan
    LABORATORY INVESTIGATION, 2023, 103 (03) : S671 - S672
  • [9] PD-L1 IHC 22C3 pharmdx demonstrates precision and reproducibility in detecting PD-L1 expression in triple negative breast cancer.
    Kulangara, Karina
    Watts, Brittany
    Vilardo, Monika
    La Placa, Christopher
    Frederick, Judith
    Tabuena-Frolli, Siena
    Jansson, Malinka
    Kersch, Kristopher
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Tumor Heterogeneity Studies using PD-L1 IHC 22C3 pharmDx on several Human Cancer Tissue Indications
    Kalpakoff, Megan
    Musser, Jeanette
    Roach, Charlotte
    Apostolaki, Angeliki
    Vilardo, Monika
    Guerrero, Lindsay
    Alvarez, Sara
    Debra, Hanks
    Welcher, Rosanne
    Kulangara, Karina
    Tabuena-Frolli, Siena
    Hund, Stephanie
    LABORATORY INVESTIGATION, 2019, 99
12345